Skip to main content

PAVmed Inc.

PAVM
Exchange
Nasdaq
Industry
Surgical & Medical Instruments & Apparatus
SEC CIK
0001624326

No open-market purchases or sales by PAVmed Inc. insiders were filed in the last 90 days; 20 institutions reported holding it in 13F filings for Q2 2026, worth $5.56M in total; no superinvestor holds it.

Currency
USD
Source
SEC XBRL data (10-K, 10-Q, 20-F, 40-F)
Updated
Nov 17, 2026, 2:21 AM ET

Income statement

Each column is one fiscal year, newest first.

Income statement of PAVmed Inc., annual
Line itemFY2025FY2024FY2023FY2022FY2021
Period endDec 31, 2025Dec 31, 2024Dec 31, 2023Dec 31, 2022Dec 31, 2021
Filing10-K10-K10-K10-K10-K
Reported––––Mar 29, 2022
Revenue$71.0K$3.00M$2.50M$377.0K$500.0K
Cost of revenue$218.0K$4.84M$6.42M$3.61M$585.0K
Gross profit––––-$85.0K
Operating expenses––––$54.3M
Research and development$4.49M$5.93M$14.3M$25.5M$19.8M
Selling, general and administrative$16.3M$24.5M$30.9M$41.0M$25.6M
Operating income-$21.8M-$44.5M-$68.8M-$90.9M-$54.4M
Interest expense–$45.0K$589.0K$1.27M–
Income tax$0––––
Net income$401.0K$39.8M-$64.2M-$89.0M-$50.3M
EPS, basic$-5.63$3.30$-9.16$-1.00–
EPS, diluted$-5.63$0.50$-9.16––
Weighted shares, basic670.5K9.67M7.23M89.1M–
Weighted shares, diluted670.5K65.3M7.23M––
Margins and growth
Gross margin––––-17.0%
Operating margin-30712.7%-1482.9%-2751.8%-24118.6%-10878.6%
Net margin564.8%1326.4%-2567.0%-23602.9%-10069.4%
Revenue growth, year over year−97.6%+20.0%+563.1%−24.6%–
Net income growth, year over year−99.0%––––

Balance sheet

Each column is one fiscal year, newest first.

Balance sheet of PAVmed Inc., annual
Line itemFY2025FY2024FY2023FY2022FY2021
Period endDec 31, 2025Dec 31, 2024Dec 31, 2023Dec 31, 2022Dec 31, 2021
Filing10-K10-K10-K10-K10-K
Reported––––Mar 29, 2022
Cash and equivalents$1.54M$1.19M$19.6M$39.7M$77.3M
Accounts receivable$15.0K$18.0K$61.0K$17.0K$200.0K
Inventory––$278.0K––
Total current assets$2.56M$2.16M$24.5M$43.9M$82.6M
Property, plant and equipment$77.0K$151.0K$1.78M$2.45M$1.58M
Intangible assets––$1.42M$3.44M$2.03M
Total assets$38.8M$30.7M$33.1M$54.0M$87.0M
Accounts payable$678.0K$657.0K$1.79M$2.70M$3.30M
Total current liabilities$14.8M$35.4M$54.2M$41.2M–
Total liabilities$16.5M$37.7M$57.1M$43.0M$7.56M
Shareholders' equity$22.3M-$7.03M-$24.0M$10.9M$79.4M

Cash flow statement

Each column is one fiscal year, newest first. Free cash flow is operating cash flow minus capital expenditures.

Cash flow statement of PAVmed Inc., annual
Line itemFY2025FY2024FY2023FY2022FY2021
Period endDec 31, 2025Dec 31, 2024Dec 31, 2023Dec 31, 2022Dec 31, 2021
Filing10-K10-K10-K10-K10-K
Reported––––Mar 29, 2022
Operating cash flow-$5.21M-$33.6M-$52.0M-$71.0M-$40.6M
Capital expenditures$31.0K$55.0K$242.0K$1.54M$1.47M
Free cash flow-$5.24M-$33.6M-$52.3M-$72.5M-$42.1M
Depreciation and amortization$105.0K$1.20M$2.93M$2.46M–
Stock-based compensation$1.71M$6.45M$11.1M$19.5M$15.0M
Investing cash flow-$31.0K-$16.2M$758.0K-$4.74M-$3.72M
Financing cash flow$5.59M$31.3M$31.2M$38.2M$104.3M
Net change in cash$353.0K-$18.5M-$20.1M-$37.5M$60.0M
Ratio
Stock-based compensation, % of revenue2404.2%215.0%445.6%5180.9%3001.8%

Shares outstanding

Common shares outstanding as stated on the cover of each 10-K and 10-Q. The date is the cover date, not the period end; a rising count means dilution.

Shares outstanding for PAVmed Inc. by cover date
Cover dateShares outstandingChange in a yearFiling
Nov 12, 20268.00M–SEC
Aug 13, 20268.00M–SEC
May 12, 20267.27M−56.7%SEC
Mar 27, 20266.38M−62.0%SEC
Mar 20, 202516.8M+83.0%SEC
Dec 31, 202411.5M−90.5%SEC
Nov 11, 202411.1M−90.8%SEC
Sep 30, 202411.0M−90.9%SEC

Notes and known gaps

How these numbers are put together, and what they can't tell you.

  • Numbers come from the XBRL data in each period's original 10-K, 10-Q, 20-F or 40-F, or its amendment. They are shown as filed: later filings don't restate earlier periods here.
  • Reported is the filing date of the first 8-K with Item 2.02 (results of operations) after the period ended, no later than the 10-Q or 10-K and within 120 days. Companies that release results only in the 10-Q, and foreign companies, which use Form 6-K, have none.

Known gaps

  • Foreign companies that file Form 20-F or 40-F have annual statements only: their quarterly results are furnished on Form 6-K, which has no XBRL data.
  • EPS and share counts are as reported at the time, not adjusted for later stock splits. Stock splits since Dec 31, 2020, from 13F share counts: 1-for-15 in Q4 2023 and 1-for-30 in Q1 2026.
  • For ADRs, EPS is per ordinary share, not per ADS (one TSMC ADS is five ordinary shares).
  • For banks, revenue may be interest income only, depending on how the bank tags its filings; cost of revenue and gross profit are usually blank.
  • Companies with several share classes, such as Berkshire Hathaway, may have no EPS and no cover share count.
  • Depreciation and amortization is missing for some companies that report it under their own XBRL tags.